Silo pharma signs agreement to develop first-in-class ketamine implant therapeutic

Initial indications are fibromyalgia and chronic pain englewood cliffs, nj, june 13, 2023 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“the company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced its entry into a research and development agreement to study and develop a dosage and time-release ketamine implant for the treatment of fibromyalgia. the research project includes analytical testing services and small batch pre-clinical proof of concept extrusion trials to determine drug release and stability.
SILO Ratings Summary
SILO Quant Ranking